Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients

Read also

Merck KGaA

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

ALS oral therapy

ALS oral therapy slows disease progression in preclinical testing

Alvotech and Advanz

Alvotech and Advanz announce EC approval for Gobivaz biosimilar